Christopher Lansdown
Family Medicine · Lucedale, MSNPI 1043420383
Payments from drug & device makers
Across 108 payments — averaging $11.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$340
- Pfizer$212
- Takeda Pharmaceuticals U.S.A., Inc.$144
- AbbVie$110
- Novo Nordisk$91
- Sunovion Pharmaceuticals Inc.$65
- plus $280 from 12 others
What the payments were for
- Food & beverage$1,22699%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $340 |
| Pfizer | 27 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $144 |
| AbbVie(2 entities) | 7 | $110 |
| Novo Nordisk | 7 | $91 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| AstraZeneca | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Merck | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Astellas Pharma US Inc | 2 | $23 |
| Amgen | 1 | $19 |
| GSK | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 2 | $11 |
How this compares
$1,241 in reported general payments places this provider in the 60th percentile of 971 family medicine providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 140 | $162,250 |
| OzempicSemaglutide | 144 | $144,569 |
| JardianceEmpagliflozin | 102 | $84,263 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $78,699 |
| JanuviaSitagliptin Phosphate | 87 | $60,609 |
| LinzessLinaclotide | 91 | $55,944 |
| XareltoRivaroxaban | 71 | $49,241 |
| RybelsusSemaglutide | 33 | $31,914 |
| EliquisApixaban | 61 | $30,695 |
| ProliaDenosumab | 14 | $22,917 |
| FarxigaDapagliflozin Propanediol | 22 | $19,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $18,743 |
| Spiriva RespimatTiotropium Bromide | 34 | $17,088 |
| RexultiBrexpiprazole | 11 | $15,779 |
| MyrbetriqMirabegron | 34 | $15,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $91 | $176,483177 claims |
| Lilly USA, LLCMounjaro | $12 | $162,250140 claims |
| MerckJanuvia | $37 | $60,60987 claims |
| AbbVieLinzess | $110 | $55,94491 claims |
| AstraZenecaFarxiga, Symbicort | $44 | $30,86767 claims |
| PfizerEliquis | $212 | $30,69561 claims |
| AmgenProlia | $19 | $22,91714 claims |
| GSKTrelegy Ellipta | $15 | $18,74330 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $43 | $15,77911 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $15,75634 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $144 | $12,34016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Lucedale
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
- Keith StokesLexington$660K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.